# Mirendil

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mirendil

- Headquarters: San Francisco, US
- Website: www.mirendil.com
- Total disclosed funding: $200M
- Latest round: Seed (Jun 25, 2026)
- Investors on record: 3

## About

Mirendil, based in the US, develops innovative AI research systems aimed at automating and enhancing scientific inquiry across various domains. The company's unique laboratory environment fosters advancements in fields such as drug discovery and robotics.Founded in 2026, Mirendil operates from San Francisco, US, focusing on self-accelerating AI research and development. The company secured a SEED funding round of USD 200 mn led by Andreessen Horowitz on June 25, 2026, contributing to their goal of enhancing scientific research capabilities. The founder's history is not detailed in the available information.Mirendil specializes in self-accelerating AI research and development, offering a unique laboratory environment designed to automate and enhance the AI research process. Their core product, the frontier lab, is engineered to produce models that not only improve over time but also facilitate the advancement of scientific inquiry across various domains such as drug discovery, chemistry, biology, and robotics. Mirendil focuses on democratizing access to these advanced AI capabilities, aiming to reduce the barriers that currently limit such expertise to a select number of laboratories. The company serves a diverse clientele that includes academic institutions, pharmaceutical companies, and research organizations globally, with specific emphasis on markets in North America, Europe, and parts of Asia. This expansive reach enables Mirendil to significantly contribute to various scientific and technological efforts that rely on AI advancements.Mirendil has successfully secured significant funding, notably a SEED round of USD 200 mn led by prominent venture capital firms, which positions the company to scale its operations effectively. The company generates revenue primarily through B2B partnerships with research institutions and commercial entities that require advanced AI solutions for their innovative projects. Clients typically engage with Mirendil through contractual agreements that may include access to their proprietary AI systems and ongoing support for integration into existing workflows. These arrangements are structured to ensure that clients can leverage Mirendil's technology for specific applications, enhancing their research capabilities while generating revenue for the firm. The focus on collaboration with large-scale organizations such as pharmaceutical companies and technology firms underscores the strategic approach to revenue generation, tapping into sectors that are increasingly reliant on AI-driven insights and solutions.In June 2026, Mirendil raised USD 200 mn in seed funding, led by Andreessen Horowitz, with participation from other investors such as Nventures and Kleiner Perkins. The company will use this funding to develop self-improving AI models that can help scientists build and optimize specialized AI systems for fields such as medicine and materials science. Mirendil aims to expand its market presence internationally, targeting additional regions in Europe and Asia by the end of 2028. This funding will support the research and development of upcoming products designed to enhance AI capabilities further.

## Funding rounds

- Seed, Jun 25, 2026, $200M — Kleiner Perkins, Andreessen Horowitz, Nventures

## Investors

- Kleiner Perkins (https://capitalatlas.ai/funds/kleiner-perkins) — Seed
- Andreessen Horowitz (https://capitalatlas.ai/funds/andreessen-horowitz) — Seed
- Nventures — Seed